WHO Raises Concern Over Severe Scarcity of Obesity Jabs

Under 10% of patients who could benefit from obesity jabs like Wegovy have access to them, caution the World Health Organization as it publishes its first advice on the medications.

With over a billion people worldwide now obese, it is advocating for increased and just availability to this class of drugs.

Per projections, more than two billion could be obese by 2030 without intervention.

"The latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with thorough and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are key hurdles to universal availability to the treatments that can aid individuals in losing significant body mass, says the organization.

Skinny Jab Scarcity

Despite the current most favorable scenario, the production of GLP-1 therapies could only cover approximately 100 million people – less than 10% of eligible patients, according to the health organization.

The advice encourages countries and companies to widen access, through approaches like patent sharing.

Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.

The Way Weight-Loss Jabs Work

The injections imitate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so users eat less.

Individuals typically start to lose weight after several weeks of commencing the regular doses.

Studies indicates people may regain a significant portion a year later of discontinuing the drug, as their typical hunger return.

To be overweight or obese elevates your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.

Obesity impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.